Journal
SCIENCE SIGNALING
Volume 10, Issue 462, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aal2328
Keywords
-
Categories
Funding
- U.S. NIH, National Cancer Institute, Center for Cancer Research
- University of Macau [SRG2014-00024-ICMS-QRCM, MYRG2016-00023-ICMS-QRCM]
- Science and Technology Development Fund [Macao S.A.R.] [014/2015/A1]
Ask authors/readers for more resources
Tumor necrosis factor receptor type II (TNFR2) is expressed both by some cancer cells and by tumor-infiltrating immunosuppressive CD4(+)FoxP3(+) regulatory T cells (T-regs). TNFR2 stimulates the activation and proliferation of T-regs, a major checkpoint of antitumor immune responses, and promotes cancer cell survival and tumor growth. In this issue of Science Signaling, Torrey et al. found that dominant antagonistic antibodies against human TNFR2 may be a potential therapy for ovarian cancer patients by simultaneously suppressing T-reg activity and inducing the death of the cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available